Collaboration and License Agreements - Fulcrum Therapeutics, Inc (Details)	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2025 USD ($)	Jul. 31, 2023 USD ($) performanceObligation milestone	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)
Collaboration and License Agreements
Research and collaboration revenue			$ 1,497,000	$ 0	$ 2,355,000	$ 0
Fulcrum Therapeutics, Inc.
Collaboration and License Agreements
Deferred revenue		$ 400,000
Number of performance obligations | performanceObligation		1
Fixed consideration amount		$ 400,000
Proceeds from milestone payment	$ 600,000
Milestone payment included in transaction price	$ 600,000
Research and collaboration revenue			$ 600,000	$ 0	$ 600,000	$ 0
Fulcrum Therapeutics, Inc. | Tier 1 Product | Minimum
Collaboration and License Agreements
Development and commercial one time milestone receivable | milestone		1
Variable consideration amount		$ 600,000
Fulcrum Therapeutics, Inc. | Tier 1 Product | Maximum
Collaboration and License Agreements
Variable consideration amount		$ 20,000,000.0